Skip to main content

DeCode s Q1 Revenues Increase 9 Percent

NEW YORK, May 16 – DeCode Genetics’ revenues rose nine percent to $5.0 million in the first quarter as milestone revenues increased.

Expenditures for the quarter more than doubled to $20.2 million, compared with $9.2 million in the year ago period as the company expanded its research activities and incurred higher general and administrative expenses.

During the first quarter, DeCode delivered schizophrenia and peripheral arterial occlusive targets to Roche as part of its alliance to develop diagnostics. The company said it expects to post near- and medium-term revenue growth stemming from milestone payments related to the five-year alliance, details of which are scheduled to be announced during the next few weeks.

DeCode of Reykjavik, Iceland, said it also entered new partnerships in gene discovery, pharmacogenomics, database services, and bioinformatics.

The company had net losses of  $16.1 million, or 37 cents a share, compared with net losses of $6.9 million, or 23 cents a share, a year ago.

As of the end of March DeCode had about $172 million in cash and cash equivalents.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.